Cardiff Oncology - Stock Price History | CRDF

Historical daily share price chart and data for Cardiff Oncology since 2021 adjusted for splits. The latest closing stock price for Cardiff Oncology as of October 27, 2021 is 5.83.
  • The all-time high Cardiff Oncology stock closing price was 1926.72 on June 08, 2005.
  • The Cardiff Oncology 52-week high stock price is 25.50, which is 337.4% above the current share price.
  • The Cardiff Oncology 52-week low stock price is 4.88, which is 16.3% below the current share price.
  • The average Cardiff Oncology stock price for the last 52 weeks is 10.50.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Cardiff Oncology Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 6.9723 1.2500 24.7100 0.7398 17.9900 1350.81%
2019 2.5236 3.4793 4.8500 1.0100 1.2400 -60.66%
2018 12.5890 21.9644 33.3427 3.0834 3.1524 -85.76%
2017 76.4910 147.6295 172.8346 18.0036 22.1444 -85.36%
2016 320.8556 373.0346 495.4591 144.0288 151.2303 -61.11%
2015 513.0598 352.8706 957.0715 310.3821 388.8778 25.58%
2014 343.1265 420.5641 485.3771 216.0432 309.6620 -25.09%
2013 488.8006 499.0599 721.5844 351.4303 413.3627 -17.17%
2012 291.7089 237.6000 533.6268 155.5511 499.0599 110.04%
2011 192.8400 207.3600 410.4000 56.1600 237.6000 5.77%
2010 211.9371 328.3200 328.3200 90.7200 224.6400 -30.67%
2009 195.2571 142.5600 341.2800 133.9200 324.0000 127.27%
2008 185.7258 289.4400 289.4400 129.6000 142.5600 -50.75%
2007 320.0070 432.0001 453.6001 216.0000 289.4400 -38.53%
2006 608.9135 803.5201 898.5601 172.8000 470.8801 -40.76%
2005 1187.8116 1728.0002 1926.7202 777.6001 794.8801 -54.00%
2004 1691.6110 1620.0002 1879.2002 1620.0002 1728.0002 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.239B $0.000B
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86